206 related articles for article (PubMed ID: 31593022)
21. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
O'Toole D; Ducreux M; Bommelaer G; Wemeau JL; Bouché O; Catus F; Blumberg J; Ruszniewski P
Cancer; 2000 Feb; 88(4):770-6. PubMed ID: 10679645
[TBL] [Abstract][Full Text] [Related]
22. A Real-World Observational Study of the Use and Associated Costs of Treating Neuroendocrine Tumors With Somatostatin Analogs in Canada.
Cheung WY; LaForty C; Liovas A; McKechnie H; Loree JM
Pancreas; 2022 Oct; 51(9):1146-1152. PubMed ID: 37078938
[TBL] [Abstract][Full Text] [Related]
23. Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis.
Gurel MH; Han Y; Stevens AL; Furtado A; Cox D
BMC Pharmacol Toxicol; 2017 Apr; 18(1):22. PubMed ID: 28372573
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
Capdevila J; Sevilla I; Alonso V; Antón Aparicio L; Jiménez Fonseca P; Grande E; Reina JJ; Manzano JL; Alonso Lájara JD; Barriuso J; Castellano D; Medina J; López C; Segura Á; Carrera S; Crespo G; Fuster J; Munarriz J; García Alfonso P
BMC Cancer; 2015 Jul; 15():495. PubMed ID: 26138480
[TBL] [Abstract][Full Text] [Related]
25. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
Öberg K; Lamberts SW
Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
[TBL] [Abstract][Full Text] [Related]
26. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis.
Shen C; Shih YC; Xu Y; Yao JC
Cancer; 2014 Jul; 120(13):2039-49. PubMed ID: 24676892
[TBL] [Abstract][Full Text] [Related]
27. INITIATION OF PATIENTS ONTO LONG-ACTING SOMATOSTATIN ANALOGUE THERAPY FOR NEUROENDOCRINE TUMORS: A SINGLE-CENTER REVIEW OF PRACTICE.
Tadman M; Charlton P; Jafar-Mohammadi B; Talbot D; Grossman AB
Endocr Pract; 2018 Feb; 24(2):189-194. PubMed ID: 29466059
[TBL] [Abstract][Full Text] [Related]
28. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
[TBL] [Abstract][Full Text] [Related]
29. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study.
Chuang CC; Bhurke S; Chen SY; Brulais S; Gabriel S
J Med Econ; 2015 Feb; 18(2):126-36. PubMed ID: 25325180
[TBL] [Abstract][Full Text] [Related]
30. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
31. Somatostatin analogues: treatment of pituitary and neuroendocrine tumors.
Colao A; Faggiano A; Pivonello R
Prog Brain Res; 2010; 182():281-94. PubMed ID: 20541670
[TBL] [Abstract][Full Text] [Related]
32. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
Amato G; Mazziotti G; Rotondi M; Iorio S; Doga M; Sorvillo F; Manganella G; Di Salle F; Giustina A; Carella C
Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
[TBL] [Abstract][Full Text] [Related]
33. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
34. Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of
Bongiovanni A; Recine F; Riva N; Foca F; Liverani C; Mercatali L; Nicolini S; Pieri F; Amadori D; Ibrahim T
Clin Lung Cancer; 2017 Jul; 18(4):415-420. PubMed ID: 27956089
[TBL] [Abstract][Full Text] [Related]
35. Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors.
Ayyagari R; Neary M; Li S; Rokito A; Yang H; Xie J; Benson AB
Am Health Drug Benefits; 2017 Nov; 10(8):408-415. PubMed ID: 29263774
[TBL] [Abstract][Full Text] [Related]
36. Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.
Harrow B; Fagnani F; Nevoret C; Truong-Thanh XM; de Zélicourt M; de Mestier L
Adv Ther; 2022 Apr; 39(4):1754-1771. PubMed ID: 35190997
[TBL] [Abstract][Full Text] [Related]
37. Costs of treatment change following first-line somatostatin analog monotherapy among patients with neuroendocrine tumors.
Tawfik B; Ray D; Moynihan M; Princic N
J Med Econ; 2021; 24(1):1337-1345. PubMed ID: 34763589
[TBL] [Abstract][Full Text] [Related]
38. Somatostatin analogues do not prevent carcinoid crisis.
Guo LJ; Tang CW
Asian Pac J Cancer Prev; 2014; 15(16):6679-83. PubMed ID: 25169508
[TBL] [Abstract][Full Text] [Related]
39. Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.
Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A; Arsof-Saab IN; Castellanos-Moreno CA; Botero L; Triana L
J Endocrinol Invest; 2023 Jan; 46(1):27-35. PubMed ID: 35913681
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]